123I Scan with Whole-Body Retention Measurement at 48 Hours for Simplified Dosimetry before 131I Treatment of Metastatic Thyroid Cancer

Jolanta M. Durski; Carrie B. Hruska; Trond V. Bogsrud; Mabel Ryder; Geoffrey B. Johnson

doi:10.1097/RLU.0000000000003464

¹²³I Scan with Whole-Body Retention Measurement at 48 Hours for Simplified Dosimetry before ¹³¹I Treatment of Metastatic Thyroid Cancer

Jolanta M. Durski, Carrie B. Hruska, Trond V. Bogsrud, Mabel Ryder, Geoffrey B. Johnson

Research output: Contribution to journal › Article › peer-review

Abstract

A previously published model (Atkins) allows for calculation of 131I maximum tolerated activity on the basis of 48-hour whole-body retention of 131I on a pretherapy diagnostic scan. Our practice uses iodine 123I for diagnostic imaging of metastatic thyroid cancer for staging before 131I therapy, with images typically acquired 24 hours after administration of the radiopharmaceutical. We explored the feasibility of an additional 123I whole-body scan and retention measurement at 48 hours, with application of the model to estimate maximum tolerated activity of radioiodine before 131I treatment of metastatic thyroid cancer.

Original language	English (US)
Pages (from-to)	e151-e153
Journal	Clinical nuclear medicine
Volume	46
Issue number	3
DOIs	https://doi.org/10.1097/RLU.0000000000003464
State	Published - 2021

Keywords

I
dosimetry
maximum tolerated activity
radioiodine retention
thyroid cancer
whole-body scan

ASJC Scopus subject areas

Radiology Nuclear Medicine and imaging

Access to Document

10.1097/RLU.0000000000003464

Cite this

@article{1738e9b1cecc41dd90aac9417698fbaf,

title = "123I Scan with Whole-Body Retention Measurement at 48 Hours for Simplified Dosimetry before 131I Treatment of Metastatic Thyroid Cancer",

abstract = "A previously published model (Atkins) allows for calculation of 131I maximum tolerated activity on the basis of 48-hour whole-body retention of 131I on a pretherapy diagnostic scan. Our practice uses iodine 123I for diagnostic imaging of metastatic thyroid cancer for staging before 131I therapy, with images typically acquired 24 hours after administration of the radiopharmaceutical. We explored the feasibility of an additional 123I whole-body scan and retention measurement at 48 hours, with application of the model to estimate maximum tolerated activity of radioiodine before 131I treatment of metastatic thyroid cancer.",

keywords = "I, dosimetry, maximum tolerated activity, radioiodine retention, thyroid cancer, whole-body scan",

author = "Durski, {Jolanta M.} and Hruska, {Carrie B.} and Bogsrud, {Trond V.} and Mabel Ryder and Johnson, {Geoffrey B.}",

year = "2021",

doi = "10.1097/RLU.0000000000003464",

language = "English (US)",

volume = "46",

pages = "e151--e153",

journal = "Clinical nuclear medicine",

issn = "0363-9762",

publisher = "Lippincott Williams and Wilkins",

number = "3",

}

TY - JOUR

T1 - 123I Scan with Whole-Body Retention Measurement at 48 Hours for Simplified Dosimetry before 131I Treatment of Metastatic Thyroid Cancer

AU - Durski, Jolanta M.

AU - Hruska, Carrie B.

AU - Bogsrud, Trond V.

AU - Ryder, Mabel

AU - Johnson, Geoffrey B.

PY - 2021

Y1 - 2021

N2 - A previously published model (Atkins) allows for calculation of 131I maximum tolerated activity on the basis of 48-hour whole-body retention of 131I on a pretherapy diagnostic scan. Our practice uses iodine 123I for diagnostic imaging of metastatic thyroid cancer for staging before 131I therapy, with images typically acquired 24 hours after administration of the radiopharmaceutical. We explored the feasibility of an additional 123I whole-body scan and retention measurement at 48 hours, with application of the model to estimate maximum tolerated activity of radioiodine before 131I treatment of metastatic thyroid cancer.

AB - A previously published model (Atkins) allows for calculation of 131I maximum tolerated activity on the basis of 48-hour whole-body retention of 131I on a pretherapy diagnostic scan. Our practice uses iodine 123I for diagnostic imaging of metastatic thyroid cancer for staging before 131I therapy, with images typically acquired 24 hours after administration of the radiopharmaceutical. We explored the feasibility of an additional 123I whole-body scan and retention measurement at 48 hours, with application of the model to estimate maximum tolerated activity of radioiodine before 131I treatment of metastatic thyroid cancer.

KW - I

KW - dosimetry

KW - maximum tolerated activity

KW - radioiodine retention

KW - thyroid cancer

KW - whole-body scan

UR - http://www.scopus.com/inward/record.url?scp=85102089385&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85102089385&partnerID=8YFLogxK

U2 - 10.1097/RLU.0000000000003464

DO - 10.1097/RLU.0000000000003464

M3 - Article

C2 - 33351514

AN - SCOPUS:85102089385

SN - 0363-9762

VL - 46

SP - e151-e153

JO - Clinical nuclear medicine

JF - Clinical nuclear medicine

IS - 3

ER -